ALZHEIMER DISEASE;
ARTICLE;
CONTROLLED STUDY;
DRUG MECHANISM;
DRUG SCREENING;
DRUG STRUCTURE;
DRUG SYNTHESIS;
ENZYME INHIBITION;
ERYTHROCYTE;
HORMONE STRUCTURE;
HUMAN;
HUMAN CELL;
INHIBITION KINETICS;
OXIDATION KINETICS;
STRUCTURE ACTIVITY RELATION;
X RAY CRYSTALLOGRAPHY;
Non-cholinergic pharmacotherapy approaches to the future treatment of Alzheimer's disease
Castro A, Conde S, Rodriguez-Franco MI et al. Non-cholinergic pharmacotherapy approaches to the future treatment of Alzheimer's disease. Mini Rev Med Chem 2002 2 : 37 50.
The cholinergic hypothesis of age and Alzheimer's disease related cognitive deficits: Recent challenges and their implications for the novel drug development
Terry AV, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer's disease related cognitive deficits: recent challenges and their implications for the novel drug development. J Pharmacol Exp Ther 2003 306 : 821 827.
Structural determinants of Torpedo californica acetylocholinesterase inhibitors by the novel and orally active carbamate based anti-Alzheimer drug ganstigmine (CHF-2819)
Bartolucci C, Siotto M, Ghidini E et al. Structural determinants of Torpedo californica acetylocholinesterase inhibitors by the novel and orally active carbamate based anti-Alzheimer drug ganstigmine (CHF-2819). J Med Chem 2006 49 : 5051 5058.
Behavioral changes after acetylocholinesterase inhibition with physostigmine in mice
Mach M, Grubbs RD, William AP. Behavioral changes after acetylocholinesterase inhibition with physostigmine in mice. Pharm Biochem Behav 2004 79 : 533 540.
Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia
Brufani M, Marta M, Pomponi M. Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia. Eur J Biochem 1986 157 : 115 120.
Phenserine and ring C hetero-analogues: Drug candidates for the treatment of Alzheimer's disease
Greig NH, Pei XF, Soncrant TT et al. Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease. Med Res Rev 1995 15 : 3 31.
Effects of MF-268, a new cholinesterase inhibitor, on acetylocholine and biogenic amines in rat cortex
Zhu XD, Cuadra G, Brufani M et al. Effects of MF-268, a new cholinesterase inhibitor, on acetylocholine and biogenic amines in rat cortex. J Neurosci Res 1996 43 : 120 126.
Cytotoxic effect of cruciferous phytoalexins against murine L1210 leukemia and B16 melanoma
Sabol M, Kutschy P, Siegfried L et al. Cytotoxic effect of cruciferous phytoalexins against murine L1210 leukemia and B16 melanoma. Biologia 2000 55 : 701 707.
Antiproliferative and cancer chemopreventive activity of phytoalexins: Focus on indole phytoalexins from crucifers
Mezencev R, Mojzis J, Pilatova M et al. Antiproliferative and cancer chemopreventive activity of phytoalexins: focus on indole phytoalexins from crucifers. Neoplasma 2003 50 : 239 245.
The cancer preventive agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYPIBI
Potter GA, Patterson LH, Wanogho E et al. The cancer preventive agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYPIBI. Brit J Cancer 2002 86 : 774 778.
Melatonin as an antioxidant: Biochemical mechanisms and pathophysiological implications in humans
Reiter RJ, Tan D-X, Mayo JC et al. Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim Pol 2003 50 : 1129 1146.
Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease with improved acetylocholinesterase inhibitory and antioxidant properties
Rodriguez-Franco MI, Fernandez-Bachiller MI, Perez C et al. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease with improved acetylocholinesterase inhibitory and antioxidant properties. J Med Chem 2006 49 : 459 462.
One molecule, many derivatives: A never ending interaction of melatonin with reactive oxygen and nitrogen species?
Tan D-X, Manchester LC, Terron MP et al. One molecule, many derivatives: a never ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007 42 : 28 42.
AFMK, a melatonin metabolite, attenuates X-ray induced oxidative damage to DNA, proteins and lipids in mice
Manda K, Ueno M, Anzai K. AFMK, a melatonin metabolite, attenuates X-ray induced oxidative damage to DNA, proteins and lipids in mice. J Pineal Res 2007 42 : 386 393.
A novel melatonin metabolite, cyclic 3-hydroxymelatonin: A biomarker of in vivo hydroxyl radical generation
Tan D-X, Manchester LC, Reiter JR et al. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem Biophys Res Com 1998 253 : 614 620.
The synthesis and the structure elucidation of N,O-diacetyl derivative of cyclic 3-hydroxymelatonin
Siwicka A, Reiter RJ, Tan D-X et al. The synthesis and the structure elucidation of N,O-diacetyl derivative of cyclic 3-hydroxymelatonin. Cent Eur J Chem 2004 2 : 425 433.
Selective inhibition of acetyl- and butyrylcholinesterases by phenylcarbamates of (-)-eseroline, (-)-(N1)-noreseroline and physovenol
Brzostowska M, He XS, Greig NH et al. Selective inhibition of acetyl- and butyrylcholinesterases by phenylcarbamates of (-)-eseroline, (-)-(N1)-noreseroline and physovenol. Med Chem Res 1992 2 : 238 246.
4-dimethylaminopyridine: An efficient and selective catalyst for the sylilation of alcohols
Chaundhary SK, Hernandez O. 4-dimethylaminopyridine: an efficient and selective catalyst for the sylilation of alcohols. Tetrahedron Lett 1979 20 : 99 102.
Anticholinesterase activity of compounds related to geneserine tautomers. N-oxides and 1,2-oxazines
Yu QS, Zhu X, Holloway W et al. Anticholinesterase activity of compounds related to geneserine tautomers. N-oxides and 1,2-oxazines. J Med Chem 2002 45 : 3684 3691.
